| Theme | Apheresis | |
|---|---|---|
| Title | Leukocytapheresis therapy for ulcerative colitis | |
| Publish Date | 1999/06 | |
| Author | Masaya Kaneda | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Koji Sawada | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Kunio Ohnishi | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Akimitsu Egashira | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Kazunobu Ohkusu | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Takako Yano | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Toshihiko Tomita | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Kazuko Nagase | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Maiko Ohdoh | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Shin Fukui | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Makoto Yamamura | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Masamichi Satomi | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| Author | Takashi Shimoyama | Fourth Department of Internal Medicine, Hyogo College of Medicine |
| [ Summary ] | Recently, the occurence of ulcerative colitis (UC) has begun to be associated with cell mediated immune responses. In 1992, we began leukocytapheresis (LCAP) therapy for patients with UC. We perfomed this therapy with leukocyte removal filters, in order to control exessive immune responses. LCAP removes white blood cells that may account for the main part of the immune responses in local lesions. In our study, 62 patients with UC were treated in two different groups ; the prednisolone (PSL) therapy group and the LCAP group (29 PSL patients and 33 LCAP). During intensive therapy, clinical improvement was seen in 34.5% of patients in the PSL group,and 69.7% of patients in the LCAP group. The incidence of adverse effects was 58.6% in the PSL group, and 24.2% in the LCAP group. The results indicate that LCAP therapy is more effective and safer than steroid therapy. LCAP therapy should be chosen for patients with UC in whom conventional drug treatments have failed or must be avoided because of their side effects. |
|